The role of peroxiredoxin II in chemoresistance of breast cancer cells

Breast Cancer: Targets and Therapy

Volumn 6, Issue , 2014, Pages 73-80

  Wang, Tieli ^a   Diaz, Anthony Joseph Gomez ^a   Yen, Yun ^b  

^a CALIFORNIA STATE UNIVERSITY   (United States)

^b CITY OF HOPE NATIONAL MEDICAL CENTER   (United States)

Author keywords

Cysteine disulfide bridges; Reactive oxygen species; Redox; siRNA; Targeted therapy

Indexed keywords

ANTINEOPLASTIC AGENT; APOPTOSIS SIGNAL REGULATING KINASE 1; APOPTOSIS SIGNALING KINASE 1; CATALASE; CISPLATIN; DOXORUBICIN; ETOPOSIDE; GLUTAREDOXIN; GLUTATHIONE; GLUTATHIONE TRANSFERASE P1; HYDROGEN PEROXIDE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; KELCH LIKE ECH ASSOCIATED PROTEIN 1; MITOGEN ACTIVATED PROTEIN KINASE; NITROGEN OXIDE; PEPTIDES AND PROTEINS; PEROXIREDOXIN; PEROXIREDOXIN 2; PEROXYNITRITE; PHAGOCYTE OXIDASE; PHOSPHATIDYLINOSITOL 3, 4, 5 TRISPHOSPHATE 3 PHOSPHATASE; PROTEIN P53; REACTIVE NITROGEN SPECIES; REACTIVE OXYGEN METABOLITE; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE; STRESS ACTIVATED PROTEIN KINASE; SUPEROXIDE DISMUTASE; THIOREDOXIN; TRANSCRIPTION FACTOR NRF2; UNCLASSIFIED DRUG; CALCIUM ACTIVATED POTASSIUM CHANNEL; CYSTEINE; DISULFIDE; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE OXIDASE; SMALL INTERFERING RNA;

ANTIOXIDANT ACTIVITY; APOPTOSIS; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER RECURRENCE; CANCER STEM CELL; CANCER THERAPY; CELL PROLIFERATION; CYTOTOXICITY; DNA DAMAGE; DNA REPAIR; GENE EXPRESSION; HIGH THROUGHPUT SEQUENCING; HUMAN; IMMUNE RESPONSE; IONIZING RADIATION; LIPID PEROXIDATION; NONHUMAN; OXIDATIVE STRESS; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN STRUCTURE; REVIEW; SIGNAL TRANSDUCTION; CANCER RADIOTHERAPY; GENE EXPRESSION REGULATION; MCF 7 CELL LINE; PHENOTYPE; PROTEIN LOCALIZATION; PROTEIN PHOSPHORYLATION; PROTEIN PROTEIN INTERACTION;

EID: 84901479010     PISSN: None     EISSN: 11791314     Source Type: Journal    
DOI: 10.2147/BCTT.S61281     Document Type: Review

References (55)

1. Breast Cancer Facts and Figures 2012-2013 [webpage on the Internet]. Atlanta: American Cancer Society, Inc. Available from: http://www.cancer.org/acs/groups/content/@epidemiologysurveilance/documents/document/acspc-033876.pdf. Accessed August 9, 2013.
2. Menaa C, Li JJ, The role of radiotherapy-resistant stem cells in breast cancer recurrence. Breast Cancer Manage Journal. 2013;2(2):89-92.
3. Abdullah LN, Chow EKH, Mechanisms of chemoresistance in cancer stem cells. Clin Trans Med. 2013;2(2):1-9.
4. Diehn M, Cho RW, Lobo NA, et al. Association of reactive oxygen species levels and radioresistance in cancer stem cells. Nature. 2009;458(7239):780-783.
5. Phillips TM, McBride WH, Pajonk F. The response of CD24(-/low)/CD44 breast cancer-initiating cells to radiation. J Natl Cancer Inst. 2006;98:1777-1785.
6. Diaz AJG, Tamae D, Yen Y, Li JJ, Wang T. Enhanced radiation response in MCF-7 radioresistant breast cancer cells by targeting peroxiredoxin II. Breast Cancer. 2013;5;87-101.
7. Duru N, Fan M, Candas D, et al. Her2-associated radioresistance of breast cancer stem cells isolated from her2-negative breast cancer cells. Clin Cancer Res. 2012;18:6634-6647.
8. Shau H, Kim A, Identification of natural killer enhancing factor as a major antioxidant in human red blood cells. Biochem Biophys Res Commun. 1994;199(1):83-88.
9. Rhee S, Kang SW, Chang TS, Jeong W, Kim K, Peroxiredoxin, a novel family of peroxidase. IUBMB Life. 2001;52(1-2):35-41.
10. Hofmann B, Hecht HJ, Flohe I. Peroxiredoxins. Biol Chem. 2002;383(3-4):347-364.
11. Smith-Pearson PS, Kooshki M, Spitz DR, Poole LB, Zhao W, Robbins ME. Decreasing peroxiredoxin II expression decreases glutathione, alters cell cycle distribution, and sensitizes glioma cells to ionizing radiation and H(2)O(2). Free Radic Biol Med. 2008;45(8):1178-1189.
12. Lu J, Holmgren, A. The thioredoxin antioxidant system. Free Radic Biol Med. 2014;66(8):75-87.
13. Lillig CH, Berndt C, Holmgren A. Glutaredoxin systems. Biochim Biophys Acta. 2008;1780(11):1304-1317.
14. Eldridge A, Fan M, Woloschak G, Grdina DJ, Chromy BA, Li JJ. Manganese superoxide dismutase interacts with a large scale of cellular and mitochondrial proteins in low-dose radiation-induced adaptive radioprotection. Free Radic Biol Med. 2012;53(10):1838-1847.
15. Wang T, Tamae D, LeBon T, Shively JE, Yen Y, Li JJ. The role of peroxiredoxin II in radiation-resistant MCF-7 breast cancer cells. Cancer Res. 2005;65(22):10,338-10,346.
16. Wangpaichitr M, Sullivan EJ, Theodoropoulos G, et al. The relationship of thioredoxin-1 and cisplatin resistance: its impact on ROS and oxidative metabolism in lung cancer cells. Mol Cancer Ther. 2012;11(3): 604-615.
17. Backos DS, Frianklin CC, Reigan P. The role of glutathione in brain tumor drug resistance. Biochem Pharmacol. 2012;83(8):1005-1012.
18. Breast Cancer Chemosensitivity. In: Yu D, Hung MC, editors. AEMB; 2007(608). Landes Bioscience and Springer Science.
19. Bae Y, Oh H, Rhee SG, Yoo YD. Regulation of reactive oxygen species generation in cell signaling. Mol Cell. 2011;32(6):491-509.
20. Poynton, RA, Hampton MB. Peroxiredoxins as biomarkers of oxidative stress. Biochim Biophys Acta. 2014;1840(2):906-912.
21. Wood ZA, Schroder E, Robin Harris J, Pool LB. Structure, mechanism and regulation of peroxiredoxins. Trends Biochem Sci. 2003;28(1): 32-40.
22. Wood ZA, Poole LB, Karplus PA. Peroxiredoxin evolution and the regulation of hydrogen peroxide signaling. Science. 2003;300(5619): 650-653.
23. Park SH, Chung YM, Lee YS, et al. Antisense of human Peroxiredoxin II enhances radiation-induced cell death. Clin Cancer Res. 2000;6:4915-4920.
24. Trachootham D, Zhang H, Zhang W, et al. Effective elimination of fludarabine-resistant CLL cells by PEITC through a redox-mediated mechanism. Blood. 2008;112(5):1912-1922.
25. Pitzschke A, Forzani C, Hirt H. Reactive oxygen species signaling in plants. Antioxid Redox Signal. 2006;8(9-10):1757-1764.
26. Halliwell B. Reactive species and antioxidants. Redox biology is a fundamental theme of aerobic life. Plant Physiol. 2006;141(2):312-322.
27. Noctor G, Veljovic-Jovanovic S, Foyer CH. Peroxide processing in photosynthesis: antioxidant coupling and redox signalling. Philos Trans R Soc Lond B Biol Sci. 2000;355(1402):1465-1475.
28. Konig J, Lotte K, Plessow R, Brockhinke A, Baier M, Dietz KJ. Reaction mechanism of plant 2-Cys peroxiredoxin. Role of the C terminus and the quaternary structure. J Biol Chem. 2003;278(27):24,409-24,420.
29. Dietz KJ, Jacob S, Oelze ML, et al. The function of peroxiredoxins in plant organelle redox metabolism. J Exp Bot. 2006;57(8):1697-1709.
30. Xue L, Zhou B, Liu X, et al. Structurally Dependent Redox Property of Ribonucleotide Reductase Subunit p53R2. Cancer Research. 2006;66(4):1900-1905.
31. Shao J, Zhou B, Di Bilio AJ, et al. A Ferrous-triapine complex mediates formation of reactive oxygen species that inactivate human ribonucleotide reductase. Mol Cancer Ther. 2006;5:586-592.
32. Wang K, Fang H, Xiao D, et al. Converting redox signaling to apoptotic activities by stress-responsive regulators HSF1 and NRF2 in fenretinide treated cancer cells. PLoS One. 2009;4(10):e7538.
33. Maillet A, Pervaiz S. Redox regulation of p53, redox effectors regulated by p53: A subtle balance. Antioxidants And Redox Signaling. 2012;16(11):1285-1294.
34. Gloire G, Piette J. Redox regulation of nuclear post-translational modifications during NF-kappaB activation. Antioxid Redox Signal. 2009;11(9):2209-2222.
35. Kansanen E, Kuosmanen SM, Leinonen H, Levonen AL. The keap1-Nrf2 pathway: Mechanisms of activation and dysregulation in cancer. Redox Biology. 2013;1(1):45-49.
36. Zhou Y, Yau C, Gray JW, et al. Enhanced NFkB and AP-1 transcriptional activity associated with antiestrogen resistant breast cancer. BMC Cancer. 2007;7(59):1-15.
37. Brandes N, Schmitt S, Jacob U. Thiol-based Redox Switches in Eukaryotic Proteins. Antioxid Redox Signal. 2008;11(5):997-1014.
38. Guo G, Wang T, Gao Q, et al. Expression of ErbB2 enhances radiation-induced NF-kappaB activation. Oncogene. 2004;23(2):535-545.
39. Wosikowski K, Regis JT, Robey RW, et al. Normal p53 status and function despite the development of drug resistance in human breast cancer cells. Cell Growth Differ. 1995;6:1395-1403.
40. Martinez-Rivera M, Siddik ZH. Resistance and gain-of-resistance phenotypes in cancers harboring wild-type p53. Biochemical Pharmacology. 2012;83:1049-1062.
41. Steelman LS, Navolanic PM, Sokolosky ML, et al. Suppression of PTEN function increases breast cancer chemotherapeutic drug resistance while conferring sensitivity to mTOR inhibitors. Oncogene. 2008;27(29):4086-4095.
42. Wang XJ, Sun Z, Villeneuve NF, et al. Nrf2 enhances resistance of cancer cells to chemotherapeutic drugs, the dark side of Nrf2. Carcinogenesis. 2008;29(6):1235-1243.
43. Torres M, Forman HJ, Redox signaling and the MAP kinase pathways. Biofactors. 2003;17(1-4):287-296.
44. Filomeni G, Auilano K, Rotilio G, Ciriolo MR, et al. Reactive oxygen species-dependent c-Jun NH2-terminal kinase/c-Jun signaling cascade mediates neuroblastoma cell death induced by diallyl disulfide. Cancer Res. 2003;63(18):5940-5949.
45. Ambruso DR. Peroxiredoxin-6 and NADPH oxidase activity. Methods Enzymol. 2013;527:145-167.
46. Sasagawa I, Matsuki S, Suzuki Y, et al. Possible involvement of the membrane-bound form of peroxiredoxin 4 in acrosome formation during spermiogenesis of rats. Eur J Biochem. 2001;268(10):3053-3061.
47. Moore RB, Mankad MV, Shriver SK, Mankad VN, Plishker GA. Reconstitution of Ca(2+)-dependent K+ transport in erythrocyte membrane vesicles requires a cytoplasmic protein. J Biol Chem. 1991;266(28):18,964-18,968.
48. Johnson RM, Goyetter G Jr, Ravindranath Y, Ho YS. Oxidation of glutathione peroxidase-deficient red cells by organic peroxides. Blood. 2002;100(4):1515-1516.
49. Rocha S, Vitorino RM, Lemos-Amado FM, et al. Presence of cytosolic peroxiredoxin 2 in the erythrocyte membrane of patients with hereditary spherocytosis. Blood Cells Mol Dis. 2008;41(1):5-9.
50. Low TY, Seow TK, Chung MC, Separation of human erythrocyte membrane associated proteins with one-dimensional and two-dimensional gel electrophoresis followed by identification with matrix-assisted laser desorption/ionization-time of flight mass spectrometry. Proteomics. 2002;2(9):1229-1239.
51. De Franceschi L, Franco RS, Bertoldi C, et al. Pharmacological inhibition of calpain-1 prevents red cell dehydration and reduces Gardos channel activity in a mouse model of sickle cell disease. FASEB. 2013;27(2):750-759.
52. Rinalducci S, D'Amici GM, Blasi B, Vaglio S, Grazzini G, Zolla L. Peroxiredoxin-2 as a candidate biomarker to test oxidative stress levels of stored red blood cells under blood bank conditions. Transfusion. 2011;51(7):1439-1449.
53. Matte A, Bertoldi M, Mohanda N, An X, et al. Membrane association of peroxiredoxin 2 in red cells is mediated by the N-terminal cytoplasmic domain of band 3. Free Radic Biol med. 2013;55:27-35.
54. Williamson AJ, Whetton AD. The requirement for proteomics to unravel stem cell regulatory mechanisms. J Cell Physiol. 2011;226(10): 2478-2483.
55. Fendler B, Atwal G. Systematic deciphering of cancer genome networks. Yale J Biol Med. 2012;85(3):339-345.